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The mechanism of action of nickel com-
pounds in the pathogenesis of several dis-
eases linked to occupational exposure has
been analyzed, but the toxicity, uptake, and
mutagenicity of nickel are not fully under-
stood. Nickel compounds exhibit differential
activities at the level of cell surface; conse-
quently, physicochemical surface interac-
tions might contribute to cell injury in
nickel-induced cytotoxicity (1). Moreover,
nickel can induce in several human and
rodent cell lines the expression of the recep-
tor system Cap43, which is involved in a
Ca2+-dependent process of signal transduc-
tion (2–4). Nickel induces CD69 expression
in lymphocyte subpopulations of allergic
patients with contact dermatitis (5). CD69
is constitutively expressed on human platelet
surface where it can be involved in signal
transduction (6). Hypernickelemia has been
found in patients with acute myocardial
infarction and has been thus related to the
pathogenesis of myocardial ischemic injuries
(7), in which platelet interactions with the
exposed collagen ﬁbers play a major role.
In previous studies we showed that
NiCl2 can enhance platelet aggregation
induced by collagen in the presence of fib-
rinogen via a rapid cytoskeletal reorganiza-
tion consequent to tyrosine phosphorylation
of pp60src, a signaling molecule that has
been detected in a submembraneous location
(8). However, nickel-induced platelet activa-
tion, expressed as p60src phosphorylation,
occurs even in the absence of fibrinogen,
whereas aggregation requires fibrinogen
binding to its receptor, integrin α IIbβ 3 (8). 
The pp60src protein is not the only pro-
tein involved in regulating the formation of
platelet cytoskeletal signaling complexes.
Calpain, a thiol protease, is responsible for the
cleavage of several adhesion structural pro-
teins (talin and integrin α IIbβ 3) (9,10) and
signaling enzymes [focal adhesion kinase
(FAK); phosphatidyl inositol 3-kinase (PIK)]
(11,12) in spreading and aggregating platelets.
Von Willebrand factor (vWf)–induced
platelet stimulation requires the coactivation
of two different glycoproteins, the GpIb-V-IX
complex and GpIIb-IIIa, or integrin α IIbβ 3,
the former being responsible for the initial
contact and the latter leading to spreading
and irreversible adhesion (13). However, vWf
binding to GpIb-V-IX complex induces the
activation and cytoskeletal association of
pp60src and PIK (14); this behavior resembles
that observed in NiCl2-treated platelets. 
Our aim was thus to verify whether the
GpIb-V-IX complex has a role in NiCl2-
induced platelet activation and to investigate
the molecules involved in the signal trans-
duction cascade that follows NiCl2 binding
to platelet membrane.
Materials and Methods
Materials. Luciferin and luciferase were
obtained from Chrono-Log (Havertown,
PA, USA). HEPES, fibrinogen, Arg-Gly-
Asp-Ser (RGDS) peptide, bovine serum
albumin (V-BSA), glucose, wortmannin,
ADP, and U46619 were obtained from
Sigma (St. Louis, MO, USA). Calpeptin
and Ro 31-8220 were obtained from
Calbiochem-Novabiochem (La Jolla, CA,
USA). Mocarhagin, lyophilized venom from
Naja mossambica mossambica, was obtained
from Latoxan (Rosans, France). And anti-
PIK, p85 (rabbit polyclonal IgG), was
obtained from Upstate Biotechnology (Lake
Placid, NY, USA). 
Platelet isolation. We collected human
platelets from drug-free, healthy donors in
acid/citrate/dextrose (ACD)-containing
tubes. Platelet-rich plasma (PRP) was
obtained after centrifugation at 180 × g for
15 min and concentrated at 800 × g for 20
min. The platelet pellet was resuspended in
one-third volume of autologous platelet-
poor plasma (PPP) and incubated with 1
mM aspirin for 15 min at 37°C. The
platelets were then washed twice in Tyrode’s
buffer (137 mM NaCl, 2.68 mM KCl, 0.42
mM NaH2PO4, 1.7 mM MgCl2) containing
10 mM HEPES (pH 6.5) and resuspended
in Tyrode’s buffer containing 0.2% BSA,
0.1% glucose, and 10 mM HEPES (pH
7.35). The final platelet suspension was
adjusted to 2.5 × 108 cells/mL.
Platelet aggregation. In vitro platelet aggre-
gation was performed in a PACKS-4 aggre-
gometer (Helena Laboratories, Beaumont,
TX, USA) using siliconized glass cuvettes at
37°C under continuous stirring. NiCl2 (1
mM and 5 mM), ADP (5 µM), and the
thromboxane A2 analog U46619 (1 µM) were
used as platelet agonists. Fibrinogen (1
mg/mL) was added before the agonists.
ATP release. Platelet activation was
stopped after 2 min by adding formalde-
hyde/EDTA according to Costa and
Murphy (15). After centrifugation at 10,000
× g for 30 sec, we measured the ATP con-
centration in the supernatant in an LKB
1251 luminometer (LKB, Turku, Finland)
after adding luciferin (40 mg/mL) and
luciferase (880 U/mL). The results were
expressed as the percentage of ATP released
relative to the total ATP present in cells
lysed by means of digitonin (50 µM) (16).
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We studied the effect of nickel ions on platelet function because hypernickelemia has been found
in patients with acute myocardial infarction. We previously demonstrated that nickel can activate
an intracellular pathway leading to cytoskeleton reorganization consequent to tyrosine phospho-
rylation of p60src in human platelets independently of integrin alpha-IIb-beta3 (α IIbβ 3).
Moreover, in von Willebrand factor–stimulated platelets, the tyrosine phosphorylation of pp60c-
src is closely associated with the activation of phosphatidylinositol 3-kinase (PIK), and two adhe-
sion receptors, glycoprotein (Gp)Ib and GpIIb/IIIa (α IIbβ 3), are involved. In our study, 1 and 5
mM nickel in the presence of ﬁbrinogen induced platelet aggregation (independently of protein
kinase C activation) and secretion. The pretreatment with a PIK inhibitor, wortmannin, strongly
decreased nickel-induced platelet aggregation. Platelet treatment with mocarhagin, a cobra venom
metalloproteinase that cleaves GpIba, signiﬁcantly reduced aggregation induced by 5 mM with-
out affecting the response to other agonists such as adenosine diphosphate (ADP). Moreover,
nickel caused PIK translocation to the cytoskeleton. Taken together, these observations suggest a
partial involvement of both integrins α IIbβ 3 and GpIb-V-IX complex in Ni2+-induced platelet
activation. Key words: adhesion receptors, integrins, nickel, platelet activation. Environ Health
Perspect 109:225–228 (2001). [Online 26 February 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p225-228riondino/abstract.htmlMocarhagin purification. We purified
mocarhagin from the crude venom of the
snake Naja mossambica mossambica for its
heparin binding properties according to De
Luca et al. (17). Briefly, crude lyophilized
venom (0.5 g) was dissolved in water (10 mL)
and loaded onto a heparin-sepharose CL-6B
column (1.5 × 40 cm; Pharmacia, Uppsala,
Sweden) at 25 mL/hr. After washing with the
column buffer containing 0.01 M Tris, 0.15
M sodium chloride, pH 7.4, bound protein
was eluted with a linear 250-mL, 0.15–1.0 M
sodium chloride gradient in 0.01 M Tris, pH
7.4. Fractions containing mocarhagin were
identified by HPLC gel-filtration using a
G2000SWXL column (15 mm, 30 cm × 7.8
mm; Supelco Inc., Bellefonte, PA, USA),
pooled, ultraconcentrated, and then loaded at
25 mL/hr onto a sepharose CL-6B column
(1.5 × 70 cm; Pharmacia). Peak eluted frac-
tions were dialyzed against the column-wash-
ing buffer. Mocarhagin (10 µg/mL) was
added to platelets 15 min (at 37°C) before
agonist stimulation.
Cytoskeleton studies. Aliquots of 500 µL
of aspirinated peptide RGDS-treated platelet
suspensions (2.5 × 108 cells/mL) were stimu-
lated with 5 mM nickel. After 1, 3, and 5 min
the reactions were stopped by the addition of
an equal volume of ice-cold Triton extraction
buffer [2% Triton X-100, 10 mM EGTA,
0.1 mM Tris, 1 mg/mL leupeptin, 20 mM
pepstatin A, 2 mM phenylmethylsulphonyl
fluoride (PMSF)]. Lysates were then cen-
trifuged at 1,500 × g for 10 min to remove
intact platelets. Triton-insoluble proteins were
isolated by centrifugation at 15,600 × g for 15
min at 4°C. Cytoskeletal proteins were sepa-
rated by 10% SDS-polyacrylamide gel elec-
trophoresis, under denaturating conditions,
and then transferred to Immobilion-P
(Millipore, Bedford, MA, USA) membranes.
The nonspeciﬁc bindings were saturated with
3% BSA. Proteins were identified with
anti–p-85 (subunit of phosphatidyl inositol 3-
kinase) polyclonal antibody, followed by
horseradish peroxidase-conjugated secondary
antibody and visualized with ECL chemilu-
minescence reaction reagent (Amersham,
Buckinghamshire, England) and Kodak X-ray
ﬁlm (X-OMAT AR; Sigma).
Results
In the presence of fibrinogen (1 mg/mL),
NiCl2 induced platelet aggregation (1 mM:
46.7 ± 9.6%; 5 mM: 78 ± 8.7%) (Figure 1)
and released ATP from the internal stores
(25.4 ± 4.5% of the total ATP present in
lysed cells vs. 3.7 ± 1.2% in the absence of
ﬁbrinogen). Control, nonstimulated platelets
produced an ATP release of 2.5 ± 0.6%
(Figure 2). 
The treatment of washed platelets with a
protein kinase C inhibitor, Ro 31-8220 (10
µM), did not modify the aggregometrical
response to 1 mM NiCl2 (data not shown)
and only slightly reduced 5 mM-induced
response (56.2 ± 2.5 vs. 78 ± 8.7 maximum
% of aggregation) (Figure 3). 
When washed platelets were treated with
a calpain selective inhibitor, calpeptin (50
µg/mL), platelet aggregation in response to
the thromboxane synthetic agonist U46619
(1 µM) was completely abolished (Figure 4,
trace a), whereas platelet response to NiCl2
was unmodiﬁed (Figure 4, trace b). 
Figure 5 shows that when washed
platelets were treated with mocarhagin (10
µg/mL), a cobra venom metalloprotease that
cleaves GpIbα , the platelet response to the
specific agonist of GpIbα  (Ristocetin) was
completely inhibited (data not shown),
whereas platelet aggregation induced by 5
mM NiCl2 in the presence of ﬁbrinogen was
significantly reduced (37.8 ± 18.6 vs. 78 ±
8.7 maximum % of aggregation), and the
response to ADP, whose action is not
exerted through GpIb-V-IX, was unaffected
(70.8 ± 12.3 vs. 71.4 ± 10.6 maximum % of
aggregation; Figure 5). 
When washed platelets were treated with
a PIK inhibitor, wortmannin (10 µM),
platelet aggregation induced by 1 mM NiCl2
was completely abolished, and the aggrega-
tion induced by 5 mM NiCl2 was strongly
decreased (36.6 ± 15.9 maximum % of
aggregation; Figure 6). 
Figure 7 shows the immunoblot analysis
of the low-speed Triton insoluble cytoskele-
tal fraction of nickel-stimulated platelets
using a polyclonal antibody directed against
the p85 subunit of PIK, closely correlated
with PtdIns 3-kinase enzymatic activity in
platelets (18). The ﬁgure shows that a faint
band, corresponding to p-85, already
detectable after 3 min NiCl2 stimulation,
became marked after 5 min stimulation of
aspirinated, RGDS-treated platelets.
Discussion
In the present study we provided evidence
that nickel can cause platelet aggregation and
ATP release from the internal stores. NiCl2
exerts these actions without entering the cell;
in fact, in unpublished observations, we
found that the addition of NiCl2 to Fura-
2–treated platelets did not quench Fura-2
fluorescence, but an evident reduction was
obtained after cellular lysis. This result was
obtained comparing the reduction of Fura-2
ﬂuorescence induced by NiCl2 to the capa-
bility of Mn2+ to totally quench the Fura-2
fluorescence after the addition of digitonin
(50 µM), according to the method described
by Sage (19).
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Figure 1. Platelet aggregation patterns in
response to 5 mM NiCl2 in (a) the absence of ﬁb-
rinogen and in the presence of fibrinogen (1
mg/mL) with (b) 1 mM NiCl2 and (c) 5 mM NiCl2.
The ﬁgure is representative of three experiments
performed.
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Figure 2. ATP release induced by 5 mM NiCl2
alone, 5 mM NiCl2 in the presence of ﬁbrinogen (1
mg/mL), and 1 µM U46619 compared to control,
unstimulated samples. The results are expressed
as the mean percentage ± SE of four experiments
performed of ATP released relative to the total
ATP present in lysed cells. Data were analyzed by
Student’s t-test for paired data.
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Figure 3. Platelet aggregation patterns in
response to 5 mM NiCl2 in the presence of ﬁbrino-
gen (1 mg/mL) in control, washed platelets (a) and
(b) after Ro 31-8220 (10 µM for 3 min at 37°C)
treatment. The figure is representative of four
experiments performed.
100
50
0
a
b
Time (min)
P
e
r
c
e
n
tMoreover, although ﬁbrinogen is essen-
tial for NiCl2-induced platelet aggregation,
it is not required for NiCl2-induced platelet
activation, expressed as p60src phosphoryla-
tion, as demonstrated by the fact that such
response is not inhibited by the incubation
with the tetrapeptide RGDS (120 µg/mL),
which prevents fibrinogen binding to its
receptor, the integrin α IIbβ 3 (8).
Many authors suggested that ﬁbrinogen
receptor exposure involves protein kinase C
(20). However, NiCl2-induced platelet
aggregation does not seem to depend on
protein kinase C activation, as demonstrated
by the observation that the treatment with a
protein kinase C inhibitor, Ro 31-8220,
only slightly modified the aggregometrical
response to NiCl2.
In a previous study (8), we demonstrated
that NiCl2 induces a rapid cytoskeletal reorga-
nization consequent to tyrosine phosphoryla-
tion of the signaling molecule p60src. Among
the key proteins regulating the formation of
platelet cytoskeletal signaling process, calpain
is not involved in NiCl2-induced triggering
of signal transduction. In fact, the treatment
with the calpain inhibitor calpeptin did not
reduce NiCl2-induced response.
Because it has been demonstrated that
pp60src translocation to the cytoskeleton is
triggered by vWf binding to GpIb-V-IX
complex, independently of ligand binding to
α IIbβ 3 (14), and that neither vWf nor
α IIbβ 3 requires calpain activation, it was
conceivable that a direct involvement of
GpIb-V-IX complex in Ni2+ evoked platelet
activation. To verify this hypothesis, we per-
formed a platelet treatment with the cobra
venom metalloprotease mocarhagin, which
cleaves GpIba. The observation of a signiﬁ-
cant reduction of platelet aggregation in
response to NiCl2 led us to hypothesize that
NiCl2 exerts its action mainly through GpIb-
V-IX. Moreover, this seems conﬁrmed by the
fact that the cytoskeletal translocation of acti-
vated pp60src, similar to what was observed
after vWf stimulation (14), was demon-
strated in NiCl2-treated platelets (8). Because
the association of p60src and PIK to
cytoskeleton occurs once platelets aggregate
(14), we tested whether the activation of PIK
was required in NiCl2-induced response. The
ﬁnding that the treatment with PIK inhibitor
wortmannin strongly decreased platelet
aggregation in response to NiCl2 indicated a
role for PIK in NiCl2-induced response.
PtdIns 3-kinase is known to translocate
from the cytosol to the membrane cytoskele-
ton in the absence of fibrinogen only after
vWf stimulation of platelets, with the ensu-
ing activation of GpIb-V-IX complex,
whereas stimulation with agonists such as
ADP, epinephrine, or collagen has no such
effect (14). In fact, vWf-induced cytoskeletal
association of PIK and pp60src occurs despite
treatment with RGDS or EDTA, which dis-
rupts the ligand-binding capacity of α IIbβ 3
but does not affect the ability of vWf to bind
GpIb-V-IX (21,22). Moreover, this last
binding is specifically blocked by an anti-
GpIb monoclonal antibody, and it is not
observed in platelets lacking the glycoprotein
Ib/IX complex (Bernard Soulier syndrome)
(14). To verify whether NiCl2-induced
platelet activation proceeds through its bind-
ing to platelet GpIb-V-IX, we studied the
cytoskeletal localization of PIK after NiCl2
addition in the absence of exogenous fib-
rinogen. The results demonstrated that
nickel was able to cause PIK translocation in
a time-dependent manner.
The fact that RGDS had no inhibitory
effect on NiCl2-induced cytoskeletal associa-
tion of PtdIns 3-kinase strongly supports the
idea that NiCl2 acts in a vWf-like manner.
Our data confirm that this step, far from
being dependent on α IIbβ 3 binding to ﬁb-
rinogen, involves other integrins, possibly
GpIb.
Taken together, these observations sug-
gest the existence of two phases in platelet
response to NiCl2 stimulation: a first step
represented by the initial contact and bind-
ing to GpIb-V-IX complex, associated with
cytoskeletal reorganization and translocation
of PIK, and a second leading to the conver-
sion of GpIIb-IIIa to an activated state nec-
essary to support platelet aggregation. To the
best of our knowledge, this is the first evi-
dence of a direct role of NiCl2 in inducing
receptor activation in platelets.
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